Meme Kanserinde Tamoksifen Kullanımına Bağlı Endometriyal Değişiklikler: Bir Olgu Sunumu

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784. doi:10.1016/S0140-6736(11)60993-8.

Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205–213. doi:10.1038/nrd1031.

Fohlin H, Nordenskjöld A, Rosell J, et al. Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up. Acta Oncol. 2024;63(6):689–698. doi:10.2340/1651-226X.2024.40493.

Mourits MJ, ten Hoor KA, van der Zee AG, Willemse PH, de Vries EG. The effects of tamoxifen on the female genital tract. Cancer Treat Rev. 2001;27(5):275–287. doi:10.1053/ctrv.2000.0222.

Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86(7):527–537. doi:10.1093/jnci/86.7.527.

Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296–300. doi:10.1016/S0140-6736(03)12342-2.

Berliere M, Dalenc F, Malingret N, et al. Incidence of endometrial pathologies after long-term use of tamoxifen in breast cancer patients. Breast Cancer Res Treat. 2011;127(2):583–589. doi:10.1007/s10549-010-1018-3.

Mourits MJ, Willemse PH, de Vries EG, et al. Monitoring endometrial changes during tamoxifen treatment in breast cancer patients. Eur J Cancer. 2002;38(7):936–940. doi:10.1016/S0959-8049(02)00015-8.

Cohen I, Beyth Y, Tepper R, et al. High frequency of endometrial pathology in postmenopausal breast cancer patients treated with tamoxifen. Gynecol Oncol. 1999;75(2):145–148. doi:10.1006/gyno.1999.5562.

van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994;343(8895):448–452. doi:10.1016/S0140-6736(94)92617-7.

Kochar SPS, Arora P, Chattopadhyay AB. Tamoxifen therapy for breast cancer and endometrial pathology. J Obstet Gynaecol India. 2005;55(6):512–515. PMID: 27407795; PMCID: PMC4922966.

Hann LE, Giess CS, Bach AM, Tao Y, Baum HJ, Barakat RR. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. AJR Am J Roentgenol. 1997;168(3):819–822. doi:10.2214/ajr.168.3.9057510.